Recap: Amgen Q4 Earnings

Shares of Amgen AMGN decreased in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share rose 4.67% year over year to $3.81, which beat the estimate of $3.39.

Revenue of $6,634,000,000 up by 7.05% from the same period last year, which beat the estimate of $6,580,000,000.

Looking Ahead

Amgen Sees FY21 Adj. EPS $16-$17 vs $17.02 Est., Sales $25.8B-$26.6B vs $26.43B Est.

How To Listen To The Conference Call

Date: Feb 02, 2021

Time: 05:00 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/wb6iw2o7

Price Action

Company's 52-week high was at $276.69

52-week low: $177.05

Price action over last quarter: Up 8.12%

Company Profile

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine).